WINNING HEALTH TECHNOLOGY GROUP CO., LTD. Financials Winning Health Technology Group Co., Ltd.
Equities
300253
CNE1000016F5
IT Services & Consulting
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.94 CNY | +2.51% |
|
+7.60% | -3.48% |
| Apr. 26 | Winning Health Technology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 19 | UBS Upgrades China's 2024 GDP Growth Forecast | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 24,584 | 37,343 | 35,967 | 21,932 | 15,340 | 14,884 | - | - |
| Enterprise Value (EV) 1 | 24,094 | 36,569 | 35,293 | 21,693 | 15,323 | 14,844 | 14,801 | 14,595 |
| P/E ratio | 61.1 x | 76.2 x | 95.2 x | 203 x | 44.1 x | 28 x | 20.6 x | 17.5 x |
| Yield | 0.17% | 0.14% | 0.12% | 0.1% | 0.28% | 0.43% | 0.5% | 0.72% |
| Capitalization / Revenue | 12.9 x | 16.5 x | 13.1 x | 7.09 x | 4.85 x | 3.85 x | 3.23 x | 3.02 x |
| EV / Revenue | 12.6 x | 16.1 x | 12.8 x | 7.01 x | 4.84 x | 3.84 x | 3.21 x | 2.96 x |
| EV / EBITDA | 51.7 x | 59.3 x | 75.8 x | 147 x | 30.3 x | 21.4 x | 16.7 x | 14.2 x |
| EV / FCF | 576,149,507 x | 179,824,589 x | 429,490,677 x | -97,322,918 x | - | - | - | - |
| FCF Yield | 0% | 0% | 0% | -0% | - | - | - | - |
| Price to Book | 6.59 x | 8.28 x | 7.2 x | 4.41 x | 2.77 x | 2.42 x | 2.2 x | 1.96 x |
| Nbr of stocks (in thousands) | 2,133,437 | 2,133,857 | 2,145,993 | 2,133,473 | 2,133,481 | 2,144,667 | - | - |
| Reference price 2 | 11.52 | 17.50 | 16.76 | 10.28 | 7.190 | 6.940 | 6.940 | 6.940 |
| Announcement Date | 2/28/20 | 4/20/21 | 4/22/22 | 4/18/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,908 | 2,267 | 2,750 | 3,093 | 3,163 | 3,870 | 4,607 | 4,925 |
| EBITDA 1 | 465.6 | 616.4 | 465.6 | 147.7 | 505.9 | 693.8 | 888.8 | 1,025 |
| EBIT 1 | 412.5 | 551.7 | 374.7 | 39.5 | 341.4 | 558.1 | 739.2 | 850.5 |
| Operating Margin | 21.62% | 24.34% | 13.62% | 1.28% | 10.79% | 14.42% | 16.05% | 17.27% |
| Earnings before Tax (EBT) 1 | 412.6 | 546.2 | 373.2 | 38.54 | 340.7 | 584.7 | 766.2 | 884.4 |
| Net income 1 | 398.4 | 491.1 | 378.2 | 108.4 | 358 | 535.3 | 724.1 | 853.3 |
| Net margin | 20.88% | 21.67% | 13.75% | 3.51% | 11.32% | 13.83% | 15.72% | 17.33% |
| EPS 2 | 0.1885 | 0.2297 | 0.1761 | 0.0506 | 0.1631 | 0.2475 | 0.3367 | 0.3967 |
| Free Cash Flow | 41.82 | 203.4 | 82.17 | -222.9 | - | - | - | - |
| FCF margin | 2.19% | 8.97% | 2.99% | -7.21% | - | - | - | - |
| FCF Conversion (EBITDA) | 8.98% | 32.99% | 17.65% | - | - | - | - | - |
| FCF Conversion (Net income) | 10.5% | 41.41% | 21.73% | - | - | - | - | - |
| Dividend per Share 2 | 0.0192 | 0.0250 | 0.0200 | 0.0100 | 0.0200 | 0.0300 | 0.0350 | 0.0500 |
| Announcement Date | 2/28/20 | 4/20/21 | 4/22/22 | 4/18/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 987.2 | 445.5 | 650.4 | 1,096 | 775 | 1,222 | 449.2 | 742.7 | 709.1 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | 37.37 | -24.8 | -108.1 | 54.66 | 124.8 |
| Operating Margin | - | - | - | - | 4.82% | -2.03% | -24.06% | 7.36% | 17.59% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - |
| Net income | 118.5 | 31.76 | 35.13 | 66.9 | - | - | - | - | - |
| Net margin | 12% | 7.13% | 5.4% | 6.1% | - | - | - | - | - |
| EPS 2 | - | - | - | - | 0.0400 | -0.0200 | -0.0296 | 0.0400 | 0.0600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/22/22 | 4/22/22 | 8/26/22 | 8/26/22 | 10/26/22 | 4/18/23 | 4/24/23 | 8/17/23 | 10/25/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 489 | 774 | 674 | 239 | 17 | 40.4 | 82.5 | 289 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | 41.8 | 203 | 82.2 | -223 | - | - | - | - |
| ROE (net income / shareholders' equity) | 11.7% | 12.5% | 7.45% | 2.15% | 6.65% | 8.2% | 10.3% | 10.8% |
| ROA (Net income/ Total Assets) | 8.52% | 8.79% | 5.58% | 1.42% | - | 6.07% | 6.93% | 6.9% |
| Assets 1 | 4,678 | 5,588 | 6,777 | 7,659 | - | 8,824 | 10,444 | 12,366 |
| Book Value Per Share 2 | 1.750 | 2.110 | 2.330 | 2.330 | 2.590 | 2.860 | 3.160 | 3.530 |
| Cash Flow per Share 2 | 0.1100 | 0.1800 | 0.1700 | 0.0500 | 0.0900 | 0.2200 | 0.2500 | 0.3800 |
| Capex 1 | 191 | 187 | 286 | 323 | 313 | 221 | 324 | 370 |
| Capex / Sales | 10.04% | 8.23% | 10.4% | 10.45% | 9.9% | 5.71% | 7.04% | 7.52% |
| Announcement Date | 2/28/20 | 4/20/21 | 4/22/22 | 4/18/23 | 4/18/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
6.94
CNY
Average target price
8.992
CNY
Spread / Average Target
+29.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.48% | 2.05B | |
| -12.23% | 194B | |
| +0.74% | 166B | |
| +2.19% | 153B | |
| +4.34% | 99.85B | |
| +7.04% | 77.56B | |
| +19.09% | 73.55B | |
| -7.30% | 71B | |
| -20.54% | 52.81B | |
| +0.53% | 47.86B |
- Stock Market
- Equities
- 300253 Stock
- Financials Winning Health Technology Group Co., Ltd.
